JP7591155B2 - 置換ピリドトリアジン化合物及びその使用 - Google Patents
置換ピリドトリアジン化合物及びその使用 Download PDFInfo
- Publication number
- JP7591155B2 JP7591155B2 JP2023543136A JP2023543136A JP7591155B2 JP 7591155 B2 JP7591155 B2 JP 7591155B2 JP 2023543136 A JP2023543136 A JP 2023543136A JP 2023543136 A JP2023543136 A JP 2023543136A JP 7591155 B2 JP7591155 B2 JP 7591155B2
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- compound
- ceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024165518A JP7759459B2 (ja) | 2021-01-19 | 2024-09-24 | 置換ピリドトリアジン化合物及びその使用 |
| JP2025030163A JP2025087755A (ja) | 2021-01-19 | 2025-02-27 | 置換ピリドトリアジン化合物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163139237P | 2021-01-19 | 2021-01-19 | |
| US63/139,237 | 2021-01-19 | ||
| US202163190461P | 2021-05-19 | 2021-05-19 | |
| US63/190,461 | 2021-05-19 | ||
| PCT/US2022/012773 WO2022159387A1 (en) | 2021-01-19 | 2022-01-18 | Substituted pyridotriazine compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024165518A Division JP7759459B2 (ja) | 2021-01-19 | 2024-09-24 | 置換ピリドトリアジン化合物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503116A JP2024503116A (ja) | 2024-01-24 |
| JP7591155B2 true JP7591155B2 (ja) | 2024-11-27 |
Family
ID=80514578
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543136A Active JP7591155B2 (ja) | 2021-01-19 | 2022-01-18 | 置換ピリドトリアジン化合物及びその使用 |
| JP2024165518A Active JP7759459B2 (ja) | 2021-01-19 | 2024-09-24 | 置換ピリドトリアジン化合物及びその使用 |
| JP2025030163A Withdrawn JP2025087755A (ja) | 2021-01-19 | 2025-02-27 | 置換ピリドトリアジン化合物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024165518A Active JP7759459B2 (ja) | 2021-01-19 | 2024-09-24 | 置換ピリドトリアジン化合物及びその使用 |
| JP2025030163A Withdrawn JP2025087755A (ja) | 2021-01-19 | 2025-02-27 | 置換ピリドトリアジン化合物及びその使用 |
Country Status (26)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024173998A (ja) * | 2021-01-19 | 2024-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | 置換ピリドトリアジン化合物及びその使用 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240151256A (ko) | 2019-03-22 | 2024-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도 |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| CN116390924B (zh) | 2020-09-30 | 2025-11-07 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
| US20250230161A1 (en) * | 2021-08-11 | 2025-07-17 | Merck Sharp & Dohme Llc | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184448A2 (en) * | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026020086A1 (en) | 2024-07-19 | 2026-01-22 | Gilead Sciences, Inc. | Methods and pharmaceutical formulations for treating viral infections |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019160783A1 (en) | 2018-02-15 | 2019-08-22 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2019230858A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | 多環性カルバモイルピリドン誘導体 |
| WO2019236396A1 (en) | 2018-06-05 | 2019-12-12 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2020075080A1 (en) | 2018-10-10 | 2020-04-16 | Janssen Biopharma, Inc. | Macrocyclic flu endonuclease inhibitors |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| WO2021007506A1 (en) | 2019-07-11 | 2021-01-14 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Compounds useful to treat influenza virus infections |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| PT2258376T (pt) | 2004-07-27 | 2019-05-31 | Gilead Sciences Inc | Análogos fosfonatados de compostos inibidores do vih |
| WO2006088173A1 (ja) | 2005-02-21 | 2006-08-24 | Shionogi & Co., Ltd. | Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体 |
| WO2006103399A1 (en) | 2005-03-31 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| DK3187225T3 (da) | 2005-04-28 | 2022-02-28 | Viiv Healthcare Co | Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet |
| JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Hivインテグラーゼ阻害活性を有する多環性化合物 |
| US20080214527A1 (en) | 2005-08-04 | 2008-09-04 | Takashi Kawasuji | Hiv Integrase Inhibitors |
| TW200800988A (en) | 2005-10-27 | 2008-01-01 | Shionogi & Amp Co Ltd | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| AU2006306355A1 (en) | 2005-10-27 | 2007-05-03 | Merck & Co., Inc. | HIV integrase inhibitors |
| TW200811153A (en) | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| WO2008010964A1 (en) | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| CA2665538A1 (en) | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US8354429B2 (en) | 2007-11-16 | 2013-01-15 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| EP2231621B1 (en) | 2008-01-08 | 2016-11-02 | Merck Sharp & Dohme Corp. | Process for preparing n-substituted hydroxypyrimidinone carboxamides |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TWI443098B (zh) | 2008-03-24 | 2014-07-01 | Medivation Technologies Inc | 吡啶并〔3,4-b〕吲哚及使用方法 |
| WO2009154870A1 (en) | 2008-05-05 | 2009-12-23 | Merck & Co., Inc. | Hiv integrase inhibitors |
| EP2247601B1 (en) | 2008-07-02 | 2013-04-10 | Avexa Limited | Thiazopyrimidinones and uses thereof |
| WO2010011812A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| ES2395705T3 (es) | 2008-07-25 | 2013-02-14 | Glaxosmithkline Llc | Compuestos químicos |
| WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| EP2660239B1 (en) | 2008-07-25 | 2016-11-23 | VIIV Healthcare Company | Chemical compounds as synthetic intermediates |
| EP2349276B1 (en) | 2008-10-06 | 2019-11-27 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| SG171308A1 (en) | 2008-12-11 | 2011-07-28 | Shionogi & Co | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| JP2012516333A (ja) | 2009-01-28 | 2012-07-19 | メルク・シャープ・エンド・ドーム・コーポレイション | Hivインテグラーゼ阻害剤としての架橋化合物 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| JP5737691B2 (ja) | 2009-06-15 | 2015-06-17 | 塩野義製薬株式会社 | 置換された多環性カルバモイルピリドン誘導体 |
| WO2011011483A1 (en) | 2009-07-22 | 2011-01-27 | Glaxosmithkline Llc | Chemical compounds |
| EP2470014A4 (en) | 2009-08-26 | 2013-01-16 | Merck Sharp & Dohme | HIV integrase inhibitors |
| WO2011045330A1 (en) | 2009-10-13 | 2011-04-21 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
| CN102858771A (zh) | 2010-02-26 | 2013-01-02 | 日本烟草产业株式会社 | 1,3,4,8-四氢-2H-吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的用途 |
| WO2011121105A1 (en) | 2010-04-02 | 2011-10-06 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| WO2011129095A1 (ja) | 2010-04-12 | 2011-10-20 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有するピリドン誘導体 |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| CN103140474A (zh) | 2010-07-02 | 2013-06-05 | 吉里德科学公司 | 治疗aids的萘-2-基乙酸衍生物 |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| SMT202100268T1 (it) | 2010-08-05 | 2021-07-12 | Shionogi & Co | Metodo per produrre composti aventi attività di inibizione di integrasi di hiv. |
| TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
| AU2011320651A1 (en) | 2010-10-29 | 2013-05-02 | Merck Canada Inc. | HIV integrase inhibitors |
| US8835411B2 (en) | 2010-12-10 | 2014-09-16 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| MX2013012266A (es) | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmaceutico. |
| CA2840095A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012321762A1 (en) | 2011-10-12 | 2014-04-17 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
| JP6144698B2 (ja) | 2011-12-20 | 2017-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hiv複製の阻害剤としての縮合三環式化合物 |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| JP2015527855A (ja) | 2012-06-25 | 2015-09-17 | サンパワー コーポレイション | 太陽電池アレイ |
| WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| US20150166520A1 (en) | 2012-07-20 | 2015-06-18 | Merck Sharp & Dohme Corp. | Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| DE102012220513B4 (de) | 2012-11-12 | 2023-02-16 | Bayerische Motoren Werke Aktiengesellschaft | Verfahren und Vorrichtung zur Herstellung eines Druckgussteils |
| EP2931730B1 (en) | 2012-12-17 | 2019-08-07 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| HK1214817A1 (en) | 2012-12-27 | 2016-08-05 | Japan Tobacco Inc. | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor |
| US9493479B2 (en) | 2013-04-16 | 2016-11-15 | Merck Sharp & Dohme Corp. | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors |
| SI2997033T1 (en) | 2013-05-17 | 2018-04-30 | Merck Sharp & Dohme Corp. | FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS |
| US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| DK3019503T3 (da) | 2013-07-12 | 2017-11-20 | Gilead Sciences Inc | Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner |
| NO2865735T3 (cg-RX-API-DMAC7.html) | 2013-07-12 | 2018-07-21 | ||
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| CA2924829C (en) | 2013-09-27 | 2019-10-29 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| NO2717902T3 (cg-RX-API-DMAC7.html) | 2014-06-20 | 2018-06-23 | ||
| WO2016027879A1 (ja) | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| WO2016033009A1 (en) | 2014-08-27 | 2016-03-03 | Bristol-Myers Squibb Company | Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication |
| WO2016090545A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
| WO2016094198A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| US10081647B2 (en) | 2015-03-26 | 2018-09-25 | Merck Sharp & Dohme Corp. | Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors |
| CA2980362C (en) | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| US10624912B2 (en) | 2015-11-17 | 2020-04-21 | Merck Sharp & Dohme Corp. | Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors |
| US10548910B2 (en) | 2015-11-17 | 2020-02-04 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors |
| EP3389380B1 (en) | 2015-12-15 | 2021-07-21 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| JP7160466B2 (ja) | 2016-06-23 | 2022-10-25 | ヴィーブ ヘルスケア カンパニー | 治療薬の送達のための組成物及び方法 |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| WO2018102634A1 (en) | 2016-12-02 | 2018-06-07 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2018109786A1 (en) | 2016-12-16 | 2018-06-21 | Cipla Limited | Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives |
| WO2018140368A1 (en) | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CN111970949A (zh) | 2018-02-13 | 2020-11-20 | 冷蒸汽解决方案公司 | 用于对气流进行加湿和冷却的方法及组合物 |
| WO2019209667A1 (en) | 2018-04-27 | 2019-10-31 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| EP3805221A4 (en) | 2018-05-31 | 2022-01-05 | Shionogi & Co., Ltd | POLYCYCLIC PYRIDONE DERIVATIVE |
| JP7394074B2 (ja) | 2018-05-31 | 2023-12-07 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 治療用化合物 |
| WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3815689A4 (en) | 2018-06-27 | 2022-04-20 | National University Corporation Hokkaido University | ARENAVIRUS GROWTH INHIBITOR WITH POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE |
| EP4751717A3 (en) | 2018-10-22 | 2026-08-05 | Board of Regents of the University of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN118873676A (zh) | 2018-11-29 | 2024-11-01 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| WO2020221294A1 (zh) | 2019-04-30 | 2020-11-05 | 上海拓界生物医药科技有限公司 | 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途 |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| TW202120510A (zh) | 2019-11-13 | 2021-06-01 | 大陸商上海拓界生物醫藥科技有限公司 | 新型四環雜環化合物及其藥物用途 |
| WO2021107065A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | 多環性ピリドピラジン誘導体 |
| US12564595B2 (en) | 2019-11-28 | 2026-03-03 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| CN116390924B (zh) | 2020-09-30 | 2025-11-07 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
| TW202227445A (zh) | 2020-10-30 | 2022-07-16 | 大陸商上海拓界生物醫藥科技有限公司 | 抑制基因缺陷的hiv病毒的用途 |
| CR20260070A (es) | 2021-01-19 | 2026-04-24 | Gilead Sciences Inc | COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315) |
| US11958864B2 (en) | 2021-02-16 | 2024-04-16 | Merck Sharp & Dohme Llc | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
-
2022
- 2022-01-18 CR CR20260070A patent/CR20260070A/es unknown
- 2022-01-18 CR CR20230315A patent/CR20230315A/es unknown
- 2022-01-18 US US17/578,020 patent/US11613546B2/en active Active
- 2022-01-18 LT LTEPPCT/US2022/012773T patent/LT4196479T/lt unknown
- 2022-01-18 FI FIEP22704452.6T patent/FI4196479T3/fi active
- 2022-01-18 HU HUE22704452A patent/HUE064467T2/hu unknown
- 2022-01-18 TW TW112143483A patent/TW202408533A/zh unknown
- 2022-01-18 CA CA3202957A patent/CA3202957A1/en active Pending
- 2022-01-18 ES ES22704452T patent/ES2968058T3/es active Active
- 2022-01-18 EP EP23205202.7A patent/EP4321217A3/en active Pending
- 2022-01-18 PL PL22704452.6T patent/PL4196479T3/pl unknown
- 2022-01-18 TW TW111102065A patent/TWI824384B/zh active
- 2022-01-18 PE PE2023002101A patent/PE20231297A1/es unknown
- 2022-01-18 JP JP2023543136A patent/JP7591155B2/ja active Active
- 2022-01-18 PT PT227044526T patent/PT4196479T/pt unknown
- 2022-01-18 HR HRP20231654TT patent/HRP20231654T2/hr unknown
- 2022-01-18 KR KR1020237027739A patent/KR20230134529A/ko active Pending
- 2022-01-18 SI SI202230013T patent/SI4196479T1/sl unknown
- 2022-01-18 EP EP22704452.6A patent/EP4196479B9/en active Active
- 2022-01-18 PE PE2024001204A patent/PE20242099A1/es unknown
- 2022-01-18 WO PCT/US2022/012773 patent/WO2022159387A1/en not_active Ceased
- 2022-01-18 MX MX2023008137A patent/MX2023008137A/es unknown
- 2022-01-18 AU AU2022210247A patent/AU2022210247C1/en active Active
- 2022-01-18 DK DK22704452.6T patent/DK4196479T5/da active
-
2023
- 2023-02-03 US US18/164,317 patent/US11897892B2/en active Active
- 2023-06-19 ZA ZA2023/06360A patent/ZA202306360B/en unknown
- 2023-07-03 IL IL304222A patent/IL304222A/en unknown
- 2023-07-17 DO DO2023000139A patent/DOP2023000139A/es unknown
- 2023-07-17 CL CL2023002074A patent/CL2023002074A1/es unknown
- 2023-07-17 CO CONC2023/0009518A patent/CO2023009518A2/es unknown
- 2023-07-18 SA SA523441639A patent/SA523441639B1/ar unknown
- 2023-12-22 US US18/393,778 patent/US12187734B2/en active Active
-
2024
- 2024-06-14 CL CL2024001793A patent/CL2024001793A1/es unknown
- 2024-09-24 JP JP2024165518A patent/JP7759459B2/ja active Active
- 2024-09-30 AU AU2024223997A patent/AU2024223997A1/en active Pending
- 2024-11-20 US US18/953,171 patent/US20250188089A1/en active Pending
-
2025
- 2025-02-27 JP JP2025030163A patent/JP2025087755A/ja not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019160783A1 (en) | 2018-02-15 | 2019-08-22 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2019230858A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | 多環性カルバモイルピリドン誘導体 |
| WO2019236396A1 (en) | 2018-06-05 | 2019-12-12 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| WO2020075080A1 (en) | 2018-10-10 | 2020-04-16 | Janssen Biopharma, Inc. | Macrocyclic flu endonuclease inhibitors |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| WO2021007506A1 (en) | 2019-07-11 | 2021-01-14 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Compounds useful to treat influenza virus infections |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024173998A (ja) * | 2021-01-19 | 2024-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | 置換ピリドトリアジン化合物及びその使用 |
| JP7759459B2 (ja) | 2021-01-19 | 2025-10-23 | ギリアード サイエンシーズ, インコーポレイテッド | 置換ピリドトリアジン化合物及びその使用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7759459B2 (ja) | 置換ピリドトリアジン化合物及びその使用 | |
| KR102934440B1 (ko) | 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도 | |
| US12122776B2 (en) | Tetracyclic compounds and uses thereof | |
| KR102240584B1 (ko) | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 | |
| CN116745292A (zh) | 经取代的吡啶并三嗪化合物及其用途 | |
| HK40104840A (en) | Substituted pyridotriazine compounds and uses thereof | |
| HK40094146B (en) | Substituted pyridotriazine compounds and uses thereof | |
| HK40094146A (en) | Substituted pyridotriazine compounds and uses thereof | |
| EA051450B1 (ru) | Замещенные соединения пиридотриазина и их применение | |
| KR20250093585A (ko) | Hiv 감염을 치료하기 위한 사환식 화합물 | |
| EA051994B1 (ru) | Тетрациклические соединения для лечения вич-инфекции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230727 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240624 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240924 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7591155 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |